In March 2012, Nobel Prize winner James Watson gave a seminar at Yale University entitled “Driven by Ideas”.
Dr. Seyfried, other than Otto Warburg himself, may well be considered the godfather of the metabolic theory of cancer.
A newly released article titled “News from the Front in War on Cancer – Mission Not Accomplished” from Scientific American highlights the flawed paradigm
Glioblastoma Multiforme (GBM) is the most aggressive form of brain cancer. Median time of survival is about 15 months from diagnosis. Standard therapy for GBM includes surgical resection followed by
In December of 2004, our 4 year old son Raffi was diagnosed with a brain tumor. After three surgeries and several failed drug protocols, it was clear that the tumor was winning. Raffi's vision, language and motor skills deteriorated and a cascade of endocrine problems affected many vital functions.
Prevention is always the best and easiest way to avoid disease. We are all aware of the lifestyle adjustments necessary to prevent heart disease and diabetes, but beyond smoking, the necessary lifestyle adjustments to prevent cancer are not always clear.
Not all scientists are created equal. We are reminded of this right now as the Nobel Prize Committee is awarding Nobel Prizes to those few who push the boundaries of science -- that ephemeral edge, dividing the know from the unknown. It is worth while to remember that many of those receiving that most coveted prize, have had to face various degrees of skepticism and derision throughout their careers -- until their ideas are ultimately proven correct in the end.
Hello, this is Travis Christofferson the founder of SCSC. For the last year I have "gone dark" while I wrote a book about the metabolic theory of cancer.
In May of 2016 we awarded a substantial grant to Dr. Thomas Seyfried's lab at Boston College. The grant is funding the exploration of a cocktail of metabolic therapies in a metastatic mouse model. The experiment will test the combination of the ketogenic diet, glycolytic inhibitors, oxygen therapy, glutamine inhibitors, exogenous ketones, and other metabolic targeting therapies in combination.
We have decided to change the name of our foundation from The Single Cause Single Cure Foundation, to The Foundation for Metabolic Cancer Therapies. We think this name better reflects our ethos. It was pointed out that perhaps Single Cause Single Cure could be interpreted as encouraging patients to seek a single cure. That is not the case. Research has clearly shown that combinations of metabolic acting therapies are synergistic, and have outcomes that far exceed any single agent. We have granted research awarded to investigate synergist "cocktails" of metabolic therapies. The preclinical work is very encouraging. Our goal is to empower patients with these largely non-toxic therapies that may greatly enhance standard of care.
This important publication documents the full remission of a patient with stage 4, triple negative breast cancer. The protocol was designed and refined at Chemothermia Oncology Center in Istanbul Turkey. Dr. Slocum and his colleagues were inspired by the research of Dr. Seyfried and others, and are pioneers in the implementation of metabolic therapies.
Your donations will be directed to keeping doctors from every having to say those words, and if they do, the next words they say will be, “but it’s going to be all right”.
We will allocate funds swiftly, with a singular purpose – to cure cancer.
The unique quality of metabolic therapies is their broad efficacy. While a given drug that targets mutations only has the potential to work on a fraction of the people with a specific type of cancer – drugs that target metabolism work on everyone with cancer, regardless of tissue of origin.
Even though this therapeutic approach has shown incredible preclinical promise, procuring funding is still difficult. The vast majority of funding continues to be allocated to research focusing on single mutations, or narrow pathways that have proven, time and time again, to be largely irrelevant to the course of the disease.
Our focused approach is unique among foundations, allowing for collaborative synergy. Not only do we directly fund research, but we will sponsor symposiums aware that innovation is born out of a collective effort.
Other foundations typically focus on one single cancer type; we focus on the one feature of cancer that pervades all cancer types – defective metabolism.
Sadly, because metabolic therapies like the ketogenic diet, hyperbaric oxygen, and re-purposed drugs are unable to be patented they sit on the side-lines.
Our goal is to fund the research that may demonstrate the efficacy of these therapies so they may be incorporated in to the oncology clinic--for everyone.
Dear friends of The Foundation for Metabolic Cancer Therapies.
To be sure, hope and optimism go hand and hand with cancer advocacy and research, and rightfully so. These are the emotions that motivate us. We’ve all heard news of a possible breakthrough, or of someone beating cancer against the odds. It’s human nature to stay hopeful and be optimistic in the face of despair. But reality portrays a different image of cancer – one much less hopeful. The statistics are a cruel reminder of the fact that we are far from winning the ‘war against cancer’ declared by President Nixon in 1971. The truth is folks, the cancer death rates today, are the same as they were in 1950. Cancer will likely soon pass heart disease as America’s leading cause of death. Many of you probably think of cancer as a disease that just affects the elderly. It’s not. Cancer is the number one killer of children and all the way up to people in their thirties.
Undeniably, meaningful progress in treating cancer has remained terribly elusive. Lifestyle changes, like a reduction in smoking rates, and earlier diagnosis, account for the vast majority of progress. New chemotherapeutic drugs account for almost nothing in terms of survival rates. In fact, one of the main therapies used to treat cancer today – radiation, has been round for 100 years. It’s hard to think of another technology that has been so stagnant.
This is unacceptable. There is something clearly wrong here.
Recent evidence implicating the importance of metabolism in cancer has not escaped the attention of some prominent researchers. DNA co-discoverer, and NCI board member, James Watson, is equally frustrated with the lack of progress, and said this recently, “More attention should be paid on the metabolism of cancer……The cancer cell should be treated as a ‘sick man’ and not a ‘superman’ by attacking cancer cells where they are metabolically vulnerable.”
Preliminary research using therapies based on exploiting the metabolic vulnerability of cancer cells has shown remarkable promise – and it has only just begun.
Our singular mission is to move forward with fresh vision -- removing all preconceived notions and entrenched bias -- and finally change the course of this insidious disease that affects us all.
Travis M. Christofferson, MS
Founder and President
We are seeking enthusiastic, and influential individuals who believe in the mission of the Single Cause Single Cure Foundation. Individuals who recognize the current approach to cancer research needs to change, and that right now this Foundation has a real chance to change the course of this awful disease.
We have a mission and a very specific research goal -- a combination of therapies directed at the metabolic defects inherent in cancer cells. (see RESTORE Protocol under the research tab)
This moment in time is unique. Decades of false promises and abject failure has led to where we are today -- but out of this failure comes new understanding. Emerging evidence combined with the knowledge acquired from decades of cancer research, has led a group of creative and critically-thinking cancer biologists to a new idea -- cancer is not a genetic disease; it is a disease of defective metabolism. This moment in time is unique because any treatment approach is only as good as the bedrock of understanding that it is based upon.
It happens that luck is on our side because there are some existing therapies that target the metabolism of cancer right now -- they happen to be cheap, relatively non-toxic, and they show incredible promise when used in combination.
Right now we think we have a real chance to impact peoples lives on a meaningful scale -- but we need help.
Founder and President